Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Monoclonal Antibody Therapeutics

What Infusion Sites, Healthcare Providers, and Patients Need to Know

​Pause in the distribution of bamlanivimab/etesevimab

ASPR has paused all distribution of bamlanivimab/etesevimab together and etesevimab alone on a national basis until further notice. In addition, FDA recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies, REGEN-COV and sotrovimab, and not use bamlanivimab/etesevimab administered together at this time. Learn More >>


Monoclonal antibody therapeutics (mAb) can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.

HHS/ASPR has purchased supplies of all COVID-19 monoclonal antibody therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.

Information for
Infusion Sites

Learn More button

Information for
Healthcare Professionals

Learn More button


Information for

Learn More button

  • This page last reviewed: July 13, 2021